Audience Discussion: Understanding What Features the FDA/EMA Assess When Approving Biomarkers in the Context of Neurodegenerative Disease Drug Development
Time: 12:00 pm
day: Track B - Day 1 AM
The difference between a successful and unsuccessful clinical trial can come down to what biomarker you choose to measure the efficacy of your therapeutic. It is critical to play close attention to just what features your selected biomarker must possess to optimize the success of your novel therapeutic in a clinical setting. Join this structured audience discussion to debate how to strategically select your next neurodegenerative biomarker in line with FDA/EMA guidelines. Learn how to optimize your approach to tackling common challenges associated with utilizing biomarkers in neurodegenerative drug development.